A
AstraZeneca
Biopharmaceutical solutions for major global diseases
About AstraZeneca
The story of AstraZeneca begins not as one, but as two separate entities across the North Sea. In Sweden, Astra AB was founded in 1913 by a group of over 400 doctors and apothecaries. Their aim was to establish domestic production of pharmaceuticals, a market dominated at the time by German and Swiss companies. One of its early successes was the local anesthetic Xylocaine. Meanwhile, in the United Kingdom, Imperial Chemical Industries (ICI), a major chemical company, decided to spin off its pharmaceuticals and agrochemicals divisions in 1993. This demerger created Zeneca Group PLC. The name 'Zeneca' was a deliberate invention, designed to be memorable and free of any unintended meanings in other languages. A pivotal moment arrived in 1999 when Astra AB and Zeneca Group merged, creating the modern-day AstraZeneca. This move was framed as a merger of equals, combining the strengths of both companies to create a new global leader in the pharmaceutical industry. The nearly $37 billion deal was one of the largest European mergers of its time. The newly formed entity established its corporate headquarters in the UK and its research and development headquarters in Sweden, reflecting its dual heritage.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1913
- Headquarters
- Cambridge, United Kingdom
- Listing
- IPO 2001
- Employees
- 76,461
- Open positions
- 434
- Dealroom signal
- 67.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Personal Health, Diabetes, Biotechnology, Oncology, Drug Development, DNA, Vaccines, Cardiology and cardiovascular, Genetics and genomics
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 79 companies, latest Sep 2026
- Capital deployed
- $2.2B
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Aug 2026 | $2.8B | — | Barclays · Goldman Sachs · Morgan Stanley | ↗ |
| POST IPO DEBT✓Debt | Feb 2026 | $2B | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for AstraZeneca is 2.5M monthly website visits, up 127.3% over the last three months. AstraZeneca's team grew 4.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Summit TherapeuticsMiami, United StatesFocused on the discovery and development of novel drug candidates to treat areas of high unmet medical need
→
Cascador/moveUPBelgiumDigital care pathways, remote monitoring and real-world evidence for life sciences
$26Mvaluation
SB
Syneron BioChinaAI-powered macrocyclic peptide drug discovery platform
$600Mvaluation
Modella AIBoston, United StatesPathChat 2 is your AI copilot for consulting on pathology cases
→
AbelZeta PharmaRockville, United StatesCell-based immunotherapies for cancer and autoimmune diseases
→
Cassidy BioIsraelAI-driven platform that designs and validates CRISPR guide RNAs by predicting efficacy, safety, and potential off-target effects
$32Mvaluation
SixPeaks BioBasel, SwitzerlandDevelops biotechnological solutions targeting muscle to support healthy weight loss and metabolic fitness
$120Mvaluation
Yaotang BioMinhang District, ChinaA biotechnology company focusing on combining LNP delivery and gene editing technology
$280Mvaluation
Sortera BioCambridge, United KingdomHarnessing Deep Screening to address the toughest challenges in biologics discovery
$40Mvaluation
NIOXOxford, United KingdomSpecialty pharmaceutical company focused on respiratory disease diagnostics
$336Mvaluation
EsoBiotecMont-Saint-Guibert, BelgiumTransforming cancer treatment with in vivo engineered CAR T cells for accelerated and easier patient access
$425Mvaluation
PathosChicago, United StatesReimagining drug discovery and development through the lens of technology, with an AI intelligence platform
$1.6Bvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
HHS Administration for Strategic Preparedness and Response
UK Research and Innovation
Series B and later3 investors entered at this stage
Barclays
Goldman Sachs
Morgan Stanley
Other known investors2 additional known investors
Medicon Village
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about AstraZeneca on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AstraZeneca’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.